{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:22:43Z","timestamp":1789885363562,"version":"4.0.1"},"reference-count":27,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1586\/14737167.7.4.319","type":"journal-article","created":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T14:54:44Z","timestamp":1187189684000},"page":"319-326","source":"Crossref","is-referenced-by-count":4,"title":["The cost\u2013effectiveness of rituximab in non-Hodgkin\u2019s lymphoma"],"prefix":"10.1586","volume":"7","author":[{"given":"Christopher","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Maciver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J. Clin."},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","year":"1997","journal-title":"Blood"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pds.600","volume":"10","author":"Paul","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"CIT0008","unstructured":"Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera\u00ae) for aggressive non-Hodgkin\u2019s lymphoma: systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 8(37), iii, ix\u2013xi, 1\u201382 (2004)."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1524-4733.2005.00037.x","volume":"8","author":"Best","year":"2005","journal-title":"Value Health"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0609.2004.00368.x","volume":"74","author":"Groot","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.20956","volume":"103","author":"Hornberger","year":"2005","journal-title":"Cancer"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0959-8049(02)00006-0","volume":"38","author":"Proctor","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"CIT0013","first-page":"463","volume":"16","author":"Uyl-de-Groot","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1705266","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bmt.1705371","volume":"37","author":"Buadi","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"CIT0016","unstructured":"NICE. Guidance for manufacturers and sponsors.Technology Appraisals Process Series No. 5.National Institute for Clinical Excellence, London, UK (2001)."},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6030","volume":"6","author":"Wake","year":"2002","journal-title":"Health Technol. Assess"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2141.1999.01515.x","volume":"106","author":"Sweetenham","year":"1999","journal-title":"Br. J. Haematol."},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01965.x"},{"key":"CIT0021","unstructured":"Roche.Achieving clinical excellence in the treatment of follicular non-hodgkin\u2019s lymphoma.Submission to NICE, London, UK (2006)."},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"CIT0023","unstructured":"Liverpool Reviews and Implementation Group.Rituximab for the first line treatment of stage III-IV follicular non-Hodgkin\u2019s lymphoma.Evidence Review Group Report for the National Institute for Health and Clinical Excellence, London, UK (2006)."},{"key":"CIT0024","first-page":"108","author":"Lepp\u00e4","year":"2006","journal-title":"Blood"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"Van Oers MHJ, Van Glabbeke M, Teodorovic Iet al.Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera\u00ae) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: final analysis of a Phase III randomized intergroup clinical trial. Presented at:American Society of Hematology 47th Annual Meeting.Georgia, GA, USA, 10\u201313 December 2005 (Abstract 353).","DOI":"10.1182\/blood.V106.11.353.353"},{"key":"CIT0026","first-page":"108","author":"Maturi","year":"2006","journal-title":"Blood"},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/10428190500052461","volume":"46","author":"Grigg","year":"2005","journal-title":"Leuk. Lymphoma"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737167.7.4.319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T21:58:34Z","timestamp":1587851914000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737167.7.4.319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,1,9]]},"published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1586\/14737167.7.4.319"],"URL":"https:\/\/doi.org\/10.1586\/14737167.7.4.319","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}